Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $137.3333.

Several research firms have weighed in on MIRM. Weiss Ratings cut Mirum Pharmaceuticals from a "sell (d)" rating to a "sell (d-)" rating in a report on Tuesday, June 23rd. Robert W. Baird set a $123.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday. Raymond James Financial reissued a "strong-buy" rating and set a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Wolfe Research began coverage on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They issued an "outperform" rating and a $145.00 target price for the company. Finally, Citizens Jmp cut their target price on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a "market outperform" rating on the stock in a research note on Thursday.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum reported second-quarter revenue of approximately $176.2 million, ahead of the $166.3 million analyst consensus and up 37.9% year over year. Growth from Livmarli and other bile-acid medicines supported the performance. Mirum Q2 earnings and 2026 outlook
• Positive Sentiment: The company raised its 2026 revenue guidance to $680 million-$700 million, above the roughly $675.1 million consensus estimate, reinforcing expectations for continued product-driven growth.
• Positive Sentiment: Despite reducing their targets, TD Cowen and HC Wainwright maintained “buy” ratings at $140, while Citizens JMP kept a “market outperform” rating with a $137 target. These targets imply substantial potential upside from recent trading levels. Analyst price target updates
• Neutral Sentiment: Analysts continue to view Mirum favorably overall, but the target reductions—from as high as $185 previously—indicate that near-term risks and valuation assumptions have become more cautious.
• Negative Sentiment: Citizens warned that the FDA made an “unexpected” request for an additional Phase 3 study, clouding Mirum’s near-term outlook. The request raises potential development costs and could delay regulatory progress, which was the primary catalyst behind the selloff. Citizens FDA assessment
• Negative Sentiment: Second-quarter earnings missed expectations: Mirum reported a larger-than-expected per-share loss, while the loss widened from the prior-year period. The company remains unprofitable, increasing investor sensitivity to clinical spending and regulatory delays. Mirum quarterly earnings report
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734 under a pre-arranged Rule 10b5-1 plan. The scheduled nature limits its significance, but the transaction reduced her direct holdings by about 59%. Mirum insider sale

Mirum Pharmaceuticals Trading Down 11.0%

Shares of MIRM opened at $94.11 on Friday. The firm has a fifty day simple moving average of $110.35 and a two-hundred day simple moving average of $101.79. Mirum Pharmaceuticals has a twelve month low of $54.74 and a twelve month high of $130.00. The stock has a market capitalization of $5.74 billion, a P/E ratio of -6.47 and a beta of 0.52. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 26.88% and a negative net margin of 139.18%.The firm had revenue of $176.24 million for the quarter, compared to analysts' expectations of $166.33 million. During the same quarter in the prior year, the company posted ($0.12) earnings per share. The business's revenue for the quarter was up 37.9% on a year-over-year basis. On average, research analysts anticipate that Mirum Pharmaceuticals will post -2.01 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $122.25, for a total transaction of $611,250.00. Following the sale, the chief financial officer directly owned 42,181 shares in the company, valued at $5,156,627.25. The trade was a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.27, for a total value of $2,445,400.00. Following the sale, the chief executive officer owned 194,309 shares in the company, valued at $23,758,161.43. This represents a 9.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 67,155 shares of company stock valued at $7,185,662. 8.32% of the stock is currently owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Cullen Frost Bankers Inc. bought a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth about $30,000. Eurizon Capital SGR S.p.A. bought a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC bought a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $32,000. State of Wyoming bought a new position in shares of Mirum Pharmaceuticals during the second quarter valued at approximately $52,000. Finally, Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals during the third quarter valued at approximately $33,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source